Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer

Divarasib demonstrated what the headline describes as best-in-class efficacy in a Phase III trial for previously treated KRAS G12C-mutated lung cancer, potentially advancing the standard of care. The headline provides no trial effect sizes, safety details, or other numerical results.